Advances in reversible covalent kinase inhibitors
Medicinal Research Reviews · 2025-03 · 45 (2) · 629-653
DOI: 10.1002/med.22084 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 17.09.2024. Verfasst von Zheng Zhao und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Data Science, University of Virginia, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Protein Kinases. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Virginia.
Abstract (Originalsprache)
Reversible covalent kinase inhibitors (RCKIs) are a class of novel kinase inhibitors attracting increasing attention because they simultaneously show the selectivity of covalent kinase inhibitors yet avoid permanent protein‐modification‐induced adverse effects. Over the last decade, RCKIs have been reported to target different kinases, including Atypical group of kinases. Currently, three RCKIs are undergoing clinical trials. Here, advances in RCKIs are reviewed to systematically summarize the characteristics of electrophilic groups, chemical scaffolds, nucleophilic residues, and binding modes. In so doing, we integrate key insights into privileged electrophiles, the distribution of nucleophiles, and hence effective design strategies for the development of RCKIs. Finally, we provide a further perspective on future design strategies for RCKIs, including those that target proteins other than kinases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Data Science, University of Virginia, Charlottesville, Virginia, USA.
- Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA.
ORCID-Profile: Zheng Zhao
Förderung
- University of Virginia
Zitieren
APA
Zhao, Z., & Bourne, P. E. (2025). Advances in reversible covalent kinase inhibitors. Medicinal Research Reviews, 45(2), 629-653. https://doi.org/10.1002/med.22084
Vancouver
Zhao Z, Bourne PE. Advances in reversible covalent kinase inhibitors. Medicinal Research Reviews. 2025;45(2):629-653. doi:10.1002/med.22084
BibTeX
@article{Zhao2025,
author = {Zhao, Zheng and Bourne, Philip E},
title = {Advances in reversible covalent kinase inhibitors},
journal = {Medicinal Research Reviews},
year = {2025},
volume = {45},
number = {2},
pages = {629--653},
doi = {10.1002/med.22084}
}
EUVIMED